Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
September 13 2017 - 3:05PM
Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company
focused on improving patients’ lives by identifying, developing,
acquiring and commercializing differentiated and accessible
medicines that address unmet medical needs, today announced that
the compensation committee of its board of directors approved the
grant on Sept. 11, 2017 of an inducement restricted stock unit
covering 64,056 ordinary shares and an inducement stock option to
purchase up to 103,138 ordinary shares to Irina Konstantinovsky,
executive vice president, chief human resources officer.
The restricted stock unit vests over four years, with 25 percent
of the shares vesting on each anniversary of the applicable vesting
commencement date, subject to the new employee's continued service
relationship with the Company. The restricted stock unit also
is subject to the terms and conditions of the Company's 2014 Equity
Incentive Plan and the restricted stock unit agreement pursuant to
which the restricted stock unit was granted.
The stock option has an exercise price per share equal to
$14.05, the fair market value on the grant date, and vests over
four years, with 25 percent of the shares vesting on the one-year
anniversary of the applicable vesting commencement date and 1/48 of
the shares vesting monthly thereafter, subject to the new
employee's continued service relationship with the Company.
The stock option also has a 10-year term and is subject to the
terms and conditions of the Company's 2014 Equity Incentive Plan
and the stock option agreement pursuant to which the option was
granted.
The restricted stock unit and stock option were granted as
inducements material to Ms. Konstantinovsky entering into
employment with Horizon Pharma on Sept. 11, 2017 in accordance with
NASDAQ Listing Rule 5635(c)(4).
About Horizon Pharma plcHorizon Pharma plc is a
biopharmaceutical company focused on improving patients' lives by
identifying, developing, acquiring and commercializing
differentiated and accessible medicines that address unmet medical
needs. The Company markets 11 medicines through its orphan,
rheumatology and primary care business units. For more
information, please visit www.horizonpharma.com. Follow
@HZNPplc on Twitter or view careers on our LinkedIn page.
Contacts:Tina VenturaSenior Vice President,
Investor RelationsInvestor-relations@horizonpharma.com
Ruth VenningExecutive Director, Investor
RelationsInvestor-relations@horizonpharma.com
U.S. Media Contact:Geoffrey CurtisSenior Vice President,
Corporate Affairs and Chief Communications
Officermedia@horizonpharma.com
Ireland Media Contact: Ray Gordon Gordon MRM
ray@gordonmrm.ie
Horizon Therapeutics Pub... (NASDAQ:HZNP)
Historical Stock Chart
From Apr 2024 to May 2024
Horizon Therapeutics Pub... (NASDAQ:HZNP)
Historical Stock Chart
From May 2023 to May 2024